GLP-1（胰高血糖素样肽1）受体激动剂、西马鲁肽和利拉鲁肽治疗肥胖2型糖尿病的相对有效性和安全性：波兰的一项前瞻性观察队列研究

IF 3 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-08-07 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S531697

Karolina Hoffmann, Michał Michalak, Anna Paczkowska

{"title":"GLP-1（胰高血糖素样肽1）受体激动剂、西马鲁肽和利拉鲁肽治疗肥胖2型糖尿病的相对有效性和安全性：波兰的一项前瞻性观察队列研究","authors":"Karolina Hoffmann, Michał Michalak, Anna Paczkowska","doi":"10.2147/DMSO.S531697","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes.Patients and methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18-80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2).Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p<0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p<0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 (p<0.0001), with greater reduction in Group 1 (p=0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI.Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"2723-2738"},"PeriodicalIF":3.0000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338098/pdf/","citationCount":"0","resultStr":"{\"title\":\"Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.\",\"authors\":\"Karolina Hoffmann, Michał Michalak, Anna Paczkowska\",\"doi\":\"10.2147/DMSO.S531697\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes.Patients and methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18-80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2).Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p<0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p<0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 (p<0.0001), with greater reduction in Group 1 (p=0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI.Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.\",\"PeriodicalId\":11116,\"journal\":{\"name\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"volume\":\"18 \",\"pages\":\"2723-2738\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338098/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DMSO.S531697\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S531697","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：比较西马鲁肽和利拉鲁肽治疗波兰肥胖2型糖尿病患者1年以上的疗效和安全性。患者和方法：这项前瞻性、观察性队列研究于2024年在波兰进行，纳入了460名年龄在18-80岁的患者：333名患者接受了西马鲁肽（1组），133名患者接受了利拉鲁肽（2组）。结果：12个月后，两组患者HbA1c水平均显著下降：1组由6.09±1.14%降至5.42±0.82%（平均下降0.67±0.37%,pppp=0.017）。胃肠道不良反应最常见，包括恶心、呕吐、便秘、胃炎和腹泻，第1组发生率更高。HbA1c降低与基线HbA1c、年龄和性别相关；BMI降低与基线HbA1c和BMI相关。结论：西马鲁肽降低HbA1c和BMI的效果优于利拉鲁肽。胃肠道症状是两组中最常见的副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.

查看原文本刊更多论文

Purpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes.

Patients and methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18-80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2).

Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p<0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p<0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 (p<0.0001), with greater reduction in Group 1 (p=0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI.

Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.